Shining light on women's health.™

Redefining the standard of care for both yeast & bacterial vaginal infections.

A prescription medical device platform that delivers controlled, visible-spectrum, microbicidal light. No hormones. No systemic drugs. A fundamentally different mechanism.

A Smarter Way to Treat Infection

A new standard in treating yeast &
bacterial infections.

Cern Corporation is advancing a prescription medical device that uses controlled, visible spectrum light to safely and effectively treat both yeast and bacterial vaginal infections without hormones or systemic drugs. A fundamentally different mechanism that holds significant promise.

Antimicrobial Resistance

Helping reduce antimicrobial resistance by decreasing antibiotic use.

Drug-Free Treatment

Addressing both yeast & bacterial infection without the use of drugs.

Birthrate & Fertility

Supporting reproductive health by addressing bacterial vaginosis.

Remote Health

Expanding access through remote women's health solutions.

The Unmet Need

A Common Condition. An Ongoing Challenge. Millions of Women Are Affected.

Vaginal infections affect hundreds of millions of women globally. The standard treatments antibiotics and antifungals leave most patients in a vicious spiral of growing drug resistance, microbiome disruption, and recurrence.

Fungal Vaginitis / Yeast

of women experience a vaginal yeast infection in their lifetime

0 %

experience 1–3 episodes per year

0 %

experience 4 or more episodes per year

6- 0 %

will have a recurrence within 12 months

0 %

Fungal Vaginitis / Yeast

of BV patients recur within 6–12 months

0 %

BV and
Birthrate

BV impacts both conception and pregnancies

Bacterial vaginosis affects as many as 30% of women, yet only 16% of these are symptomatic. This becomes very significant, especially in conception and healthy full-term delivery. Many women have BV but are not aware.

0 %

Many women who are recurrent, may suffer both yeast and bacterial infections simultaneously. Cern’s treatment uniquely addresses both.